Non-invasive micro-stimulation treatments

With all of its negative connotations, electroconvulsive therapy (ECT) was traditionally a frequent treatment for those diagnosed with depression that was not responsive to other approaches. While the method may be useful in certain situations, the adverse effects on cognition and memory are frequently too severe for patients to handle.

Today, rather than using ECT to treat treatment-resistant depression, mental health providers now have the option of leveraging transcranial magnetic stimulation (TMS). This technology utilizes magnetic fields to stimulate neurons in a beneficial, non-invasive way. The non-invasive magnetic pulses of TMS reduce the symptoms of depression without the use of medication or other intrusive treatments by targeting the specific parts of the brain responsible for mood control.

In practice, researchers from various US-based universities found that TMS can effectively treat veterans with major depressive disorder, including those with signs of post-traumatic stress disorder, according to a study of 700 US participants.

Psychedelics supporting mental diseases treatments

Ketamine, a once-banned substance, has recently been repurposed to treat depression and is now accessible to the public, ever for delivery. People are increasingly micro-dosing LSD to relieve anxiety caused by the pandemic and Wall Street is investing billions in companies that market mind-altering pharmaceuticals.

Although illegal in many countries, psychedelics have started to garner more and more government support, as they have proven effective when appropriately dosed. There is mounting research indicating that chemicals like psilocybin, MDMA, DMT and cannabidiol (CBD) can assist in treating mental illness that has not responded to conventional drug treatments when used in a controlled context and accompanied by professional care.

For example, the Australian government has shown its support for psychedelics by granting nearly $15 million for innovative mental clinical trials. They believe that the funds invested in research will potentially deliver ground-breaking treatments for those suffering from chronic mental illnesses such as significant depression with alcohol use, anorexia nervosa, PTSD and anxiety disorders.

In fact, the largest amount, totaling more than $3.8 million, will go to a University of Melbourne research team for a trial of MDMA-assisted psychotherapy for treatment-resistant social anxiety in young adults with an autism spectrum disorder.

However, regulatory issues may present a barrier to greater adoption. Several countries across the world are known for their firm anti-drug stance, such as Mexico. For the foreseeable future, these countries and many others will be unwilling to invest time and resources in new regulatory frameworks even if relevant research is supplied, since they see psychedelic-based medications as inherently unethical.

Digital tools to track mental health conditions

Technology may be a helpful first step for those who have previously avoided mental health treatment. Consumers are turning their mobile devices into pocket therapists, be it with meditation platforms such as Headspace and Calm, or with telemedicine services, including Klara and Steth IO.

There is even an artificial intelligence (AI)-based platform called Quartet that identifies at-risk patients by assessing medical records, adjusting mental health paths and suggesting professional help if needed. Moreover, mental health bots are gaining popularity. Woe Bot, Mood kits and Mood notes are the most popular on today’s market. They employ cognitive behavioral therapy (CBT) and various strategies to assist individuals in improving their mental health.

Another novel way of leveraging today’s technology is social media data collection to detect self-harm trends and tendencies among users through AI. In the mental health space, AI adoption is still in its infancy, yet it could be the biggest game-changer of the twenty-first century.

It remains worth noting that mental health app providers face their challenges, too. One of those might be obtaining empirical evidence that technological interventions work and operate as well as – or even better – than traditional approaches. Experts also notice that a particular difficulty could be equity – assessing whether apps work for all people and all mental health conditions. Apart from that, app producers and developers must be able to guarantee users’ privacy as apps tend to deal with very sensitive personal information.

An additional concern is a threat of overselling. Within mental health app providers, it needs to be acknowledged that customers may abandon it if an app or program promises more than it can provide. It is therefore vital that the users can get fair value from the service.

VR assisting in traditional psychotherapeutic treatments

For quite some time, virtual reality (VR) has progressed in various therapy fields. By the end of 2021, the US Food and Drug Administration (FDA) approved the marketing of EaseVRx, a prescription-only VR device. Aimed at patients over 18-years-old, EaseVRx uses CBT and other psychological approaches to target chronic lower back pain symptoms. Now is the time to embrace this technology in mental healthcare.

An international research collaboration of UK and Canadian universities shows that VR-based programs effectively treat conditions such as public speaking anxiety. Now, Japan-based company Jolly Good is creating a state-of-the-art technology called VRDTx, which employs CBT approaches.

Moreover, meta-analysis from JMIR Mental Health implicates that VR effectively supports CBT in treating anxiety and depression in the majority of trials.

Although it is a relatively new technology in the psychological field, because of its adaptability, VR may be used to treat various mental health issues, such as anxiety issues, PTSD and addiction. It is the future of low- to moderate-risk devices of a new type.

Towards new targeted treatments

Another significant improvement in clinical psychiatry would be defining narrower patient groups based on their biomarkers. This could contribute to increased treatment response rates in specific subgroups. For example, a study published in Nature Reviews Drug Discovery shows that immune dysregulation, reflected in increased levels of inflammatory biomarkers, is highly associated with major depressive disorder (MDD).

How do we know we can target specific biomarkers in people suffering from severe depression? For instance, research indicates that patients suffering MDD with inflammation (CRP >3mg/L) performed worse on neurocognitive tests in psychomotor speed and response time. Overall, patients with MDD and high pro-inflammatory biomarkers are less likely to react to traditional antidepressants. Those unresolved clinical issues could be dealt with by implementing innovative immune-based therapies.

Whether it is patients’ own motivation to maintain their mental health via mobile platforms or they are indirectly using novel technology through professionals in more severe cases, the improvement and development of innovative treatments of mental health disorders cannot slow down. Experts need to keep the momentum and aim for even more disruptive solutions to ensure our society’s best chances for balanced wellbeing.